Our Pricing

Buy Mounjaro Single Pen - All Doses Available

Published on: June 03, 2026

Looking to buy Mounjaro single pen UK online with flexible dosing options? Cured Pharmacy offers genuine UK-licensed Mounjaro KwikPens from £124.99 with all doses available subject to clinical assessment by our UK prescribers. Our transparent pricing and free online consultation make accessing this advanced weight loss treatment straightforward and discreet.

Understanding Mounjaro Single Pen Options

Mounjaro (tirzepatide) KwikPens are available in five dose strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg, each delivered as a once-weekly subcutaneous injection [1]. The single pen format provides flexibility for patients who prefer to purchase individual pens rather than committing to multi-pen packs, particularly during dose titration phases.

Each Mounjaro KwikPen contains four doses of the same strength, designed for once-weekly administration over four weeks. The pen device features a simple push-button mechanism and pre-attached needle, eliminating the need for manual injection preparation. This design has been shown to improve treatment adherence compared to traditional vial-and-syringe systems [2].

Your prescribed dose depends on your individual response and tolerability. UK prescribers typically initiate treatment at 2.5mg weekly for four weeks, then increase to 5mg for another four weeks, with further titration as clinically appropriate. This gradual escalation minimises gastrointestinal side effects whilst optimising weight loss outcomes [1].

How Mounjaro Delivers Superior Weight Loss Results

Mounjaro contains tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management [1]. This dual mechanism distinguishes it from single-pathway GLP-1 treatments, activating two complementary hormonal systems that regulate appetite, energy expenditure, and glucose metabolism.

In the landmark SURMOUNT-1 trial, participants receiving the 15mg dose achieved an average 22.5% reduction in body weight over 72 weeks—significantly greater than the 14.9% seen with semaglutide 2.4mg in comparative analyses [1][3]. More than half of participants on the highest tirzepatide dose lost at least 20% of their baseline weight, a threshold associated with substantial improvements in obesity-related comorbidities.

The medication works by slowing gastric emptying, reducing appetite through central nervous system pathways, and improving insulin sensitivity. Patients typically report feeling fuller for longer periods and experiencing fewer food cravings, making it easier to maintain the caloric deficit necessary for sustained weight loss [1].

Clinical Evidence Supporting Mounjaro

The SURMOUNT clinical trial programme enrolled over 5,000 participants across multiple studies, demonstrating consistent efficacy across diverse populations. In SURMOUNT-3, participants who continued tirzepatide after an initial weight loss phase maintained their results, whilst those switched to placebo regained significant weight—highlighting the importance of ongoing treatment for long-term weight management [3].

Beyond weight reduction, clinical trials documented improvements in cardiovascular risk markers including blood pressure, lipid profiles, and inflammatory markers. These metabolic benefits occurred independently of weight loss, suggesting direct cardioprotective effects of tirzepatide [1][3].

Mounjaro vs Wegovy: Comparing Your Options

Both Mounjaro and Wegovy are MHRA-licensed injectable medications for chronic weight management, but they differ in mechanism and clinical outcomes. Wegovy contains semaglutide, a GLP-1 receptor agonist, whilst Mounjaro's tirzepatide activates both GIP and GLP-1 receptors—a dual action that appears to produce greater weight loss in head-to-head comparisons [3].

In network meta-analyses comparing weight loss medications, tirzepatide 15mg demonstrated superior efficacy to semaglutide 2.4mg, with an additional 7-8% body weight reduction on average [3]. However, both medications share similar side effect profiles, predominantly gastrointestinal symptoms that typically diminish over time with continued use.

Your UK prescriber will consider multiple factors when recommending treatment, including your weight loss goals, medical history, previous treatment responses, and personal preferences. Some patients may start with one medication and switch to another based on tolerability or efficacy, a decision made collaboratively with your clinical team.

Starting Your Mounjaro Treatment at Cured Pharmacy

Accessing Mounjaro through Cured Pharmacy begins with a free online consultation that takes under three minutes to complete. Our UK-registered prescribers review your medical history, current medications, and weight loss goals to determine whether Mounjaro is clinically appropriate for you. This assessment is mandatory for all prescription medications and ensures your safety throughout treatment.

If approved, your prescription is sent directly to our UK-registered pharmacy (GPhC 9012511), where Superintendent Pharmacist Tarun Kumar (GPhC 2233073) and his team dispense genuine UK-licensed medications. We source all Mounjaro pens directly from licensed UK wholesalers, guaranteeing authenticity and proper storage conditions throughout the supply chain.

Your medication arrives in 100% discreet packaging with no external branding, typically within 2-3 working days via Royal Mail or courier service. Each delivery includes the prescribed Mounjaro pen, patient information leaflet, and guidance on injection technique. Our clinical team remains available for follow-up questions throughout your treatment journey.

Ongoing Clinical Support

Weight loss medication works best as part of a comprehensive approach including dietary modifications and increased physical activity. Our prescribers provide personalised guidance on lifestyle adjustments that complement your medication, optimising your results whilst building sustainable habits for long-term weight maintenance.

Regular follow-up assessments monitor your progress, side effects, and any dose adjustments needed. Most patients require dose titration every four weeks during the initial months, gradually increasing to the optimal maintenance dose based on individual response and tolerability.

Common Side Effects and How to Manage Them

The most frequently reported side effects of Mounjaro are gastrointestinal, including nausea, diarrhoea, decreased appetite, vomiting, and constipation [1]. In clinical trials, these symptoms were generally mild to moderate in severity and decreased over time as patients adapted to the medication. Starting at the lowest dose and titrating gradually minimises these effects.

Nausea affects approximately 20-30% of patients during dose escalation but typically resolves within a few weeks [1]. Practical strategies include eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and taking the injection at bedtime so peak effects occur during sleep. If symptoms persist, your prescriber may slow the titration schedule or recommend anti-nausea medications.

Serious adverse events are rare but include potential risks of pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients taking other diabetes medications). Mounjaro carries a boxed warning regarding thyroid C-cell tumours observed in animal studies, though no causal relationship has been established in humans [1]. Your prescriber will assess your risk factors during the initial consultation.

Who Can Use Mounjaro and Important Contraindications

Mounjaro is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia [1]. Your prescriber calculates your BMI during the online assessment and evaluates whether you meet the clinical criteria for treatment.

The medication is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, those with a history of severe gastrointestinal disease, and women who are pregnant or breastfeeding [1]. Mounjaro has not been studied in patients under 18 years or over 75 years, and caution is advised in these populations.

Certain medications may interact with Mounjaro, particularly those affecting blood glucose levels or gastric emptying. Oral contraceptives may have reduced absorption due to delayed gastric emptying, so additional contraceptive measures are recommended for four weeks after starting Mounjaro and after each dose increase [1]. Your prescriber reviews all current medications during your assessment to identify potential interactions.

Special Considerations

Patients with a history of diabetic retinopathy should be monitored closely, as rapid glucose improvements have been associated with temporary worsening of retinopathy in some GLP-1 receptor agonist trials [1]. Those with renal impairment can generally use Mounjaro, though increased monitoring for dehydration from gastrointestinal side effects is recommended.

If you're currently taking other weight loss medications, your prescriber will advise whether these should be discontinued before starting Mounjaro. Combining multiple weight loss treatments is not recommended and may increase the risk of adverse effects without additional benefit.

Scientific References

1. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency. https://www.medicines.org.uk/emc/product/14298 [accessed 13 August 2026]
2. Matfin, G., Van Brunt, K., & Zimmermann, A. G. (2018). Safe and effective use of the once weekly dulaglutide single-dose pen in injection-naïve patients with type 2 diabetes. Journal of Diabetes Science and Technology, 9(5), 1071-1079. https://doi.org/10.1177/1932296815583059 [accessed 13 August 2026]
3. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on multiple factors including adherence to treatment, dietary modifications, and physical activity levels.